Ardelyx, Inc. (ARDX) · Aug 6, 2026 · Company update

Strong quarter overshadowed by a sharp IBSRELA guidance cut

Strong quarter overshadowed by a sharp IBSRELA guidance cut

The quarter missed a high bar despite 31% growth. Total product revenue reached $118.1 million versus $90.1 million a year earlier, but came in below the published consensus of roughly $124.8 million; EPS of negative $0.07 also trailed expectations around negative $0.05 to negative $0.06.

$ in millions, except EPSQ2 2026Q2 2025YoY changePublished expectation
IBSRELA revenue$86.2$65.033%—
XPHOZAH revenue$31.9$25.027%—
Total product revenue$118.1$90.131%~$124.8
Net loss$(16.7)$(19.1)12% better—
EPS$(0.07)$(0.08)13% better~$(0.05) to ~$(0.06)
R&D expenses$26.1$15.767%—
SG&A expenses$101.4$84.021%—

(Financial Highlights)

The decisive issue is the IBSRELA outlook, not the reported growth. Ardelyx cut 2026 IBSRELA revenue guidance from $410–430 million to $350–370 million, a reduction of roughly 14% at the midpoint. Management cited payor requirements affecting new patient starts and access, meaning the problem is increasingly about prescription conversion and reimbursement friction rather than a lack of physician or patient demand. (Corporate Outlook; Commercial Update)

XPHOZAH remains a stabilizer, but not enough to offset the core downgrade. Q2 XPHOZAH revenue rose 27% to $31.9 million, with paid prescriptions up 25% and total dispenses up 33%. Its full-year revenue outlook of $110–120 million was reiterated, but that business is much smaller than IBSRELA and therefore cannot compensate for the lowered flagship-product trajectory. (XPHOZAH Commercial Update; Corporate Outlook)

The profitability path is still intact on paper, but the quality of the improvement is mixed. Operating expenses rose 28% year over year to $127.5 million, including a 67% increase in R&D, while the net loss narrowed to $16.7 million. Ardelyx lowered its 2026 operating-expense outlook from up to $520 million to below $500 million, which helps near-term cash control but also reflects a more cautious growth environment. Cash and investments were $281.8 million at June 30, including a $50 million debt drawdown, so the balance sheet is stronger than year-end but partly supported by additional borrowing. (Financial Highlights; Corporate Outlook)

Net read: operational momentum beat the prior-year comparison, but the reset to near-term expectations is materially worse. The unchanged long-term $1 billion IBSRELA ambition and reiterated XPHOZAH outlook preserve the broader story, yet the 2026 guidance cut signals that market-access headwinds will delay the revenue ramp and potentially the timing of the longer-term target. (Corporate Outlook)

Original filing on SEC EDGAR

More Ardelyx, Inc. news

Strong quarter overshadowed by a sharp IBSRELA guidance cut | ARDX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.